EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during carcinogenesis. Enhancer of Zeste 2 (EZH2) is the histone methyltransferase subunit in polycomb repressive complex 2 which mediates transcriptional repression through histone methylation. EZH2 overexpression has b...
Main Authors: | Wei Cao, Rachel de Oliveira Ribeiro, Diane Liu, Pierre Saintigny, Ronghui Xia, Yuwen Xue, Ruxian Lin, Li Mao, Hening Ren |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3534094?pdf=render |
Similar Items
-
CDC25A(Q110del): a novel cell division cycle 25A isoform aberrantly expressed in non-small cell lung cancer.
by: Rania H Younis, et al.
Published: (2012-01-01) -
RCC1 functions as a tumor facilitator in clear cell renal cell carcinoma by dysregulating cell cycle, apoptosis, and EZH2 stability
by: Yunfei Wu, et al.
Published: (2023-10-01) -
Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas
by: Franziska Lea Schümann, et al.
Published: (2021-12-01) -
EZH2 in Myeloid Malignancies
by: Jenny Rinke, et al.
Published: (2020-07-01) -
Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
by: Su, I-hsin, et al.
Published: (2013)